MaxCyte (NASDAQ:MXCT) Trading Down 9.3%

MaxCyte, Inc. (NASDAQ:MXCTGet Rating)’s stock price fell 9.3% during mid-day trading on Friday . The company traded as low as $5.50 and last traded at $5.56. 3,514 shares were traded during trading, a decline of 99% from the average session volume of 658,173 shares. The stock had previously closed at $6.13.

Analyst Ratings Changes

Separately, BTIG Research boosted their price objective on MaxCyte from $10.00 to $11.00 and gave the stock a “buy” rating in a report on Sunday, August 14th.

MaxCyte Price Performance

The company has a fifty day moving average of $5.62.

Insider Activity at MaxCyte

In related news, major shareholder Casdin Partners Master Fund, L sold 3,235,548 shares of the business’s stock in a transaction that occurred on Friday, July 1st. The stock was sold at an average price of $4.30, for a total value of $13,912,856.40. Following the completion of the sale, the insider now directly owns 10,735,786 shares in the company, valued at $46,163,879.80. The sale was disclosed in a filing with the SEC, which is available at this link. 5.11% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On MaxCyte

Several institutional investors have recently made changes to their positions in MXCT. Strs Ohio boosted its stake in shares of MaxCyte by 588.9% in the first quarter. Strs Ohio now owns 24,800 shares of the company’s stock valued at $173,000 after buying an additional 21,200 shares during the period. Nkcfo LLC bought a new stake in shares of MaxCyte in the first quarter valued at approximately $91,000. Vitruvian Partners LLP boosted its stake in shares of MaxCyte by 31.7% in the first quarter. Vitruvian Partners LLP now owns 4,385,670 shares of the company’s stock valued at $30,656,000 after buying an additional 1,055,670 shares during the period. Freemont Management S.A. acquired a new position in MaxCyte during the first quarter valued at approximately $68,000. Finally, Qube Research & Technologies Ltd acquired a new position in MaxCyte during the first quarter valued at approximately $280,000. 66.40% of the stock is currently owned by institutional investors.

MaxCyte Company Profile

(Get Rating)

MaxCyte, Inc, a global life sciences company, engages in the discovery, development, and commercialization of next-generation cell therapies. Its products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering.

Featured Stories

Receive News & Ratings for MaxCyte Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MaxCyte and related companies with MarketBeat.com's FREE daily email newsletter.